Stratec biomedical under pressure: loss of sales and job cuts threaten!

Stratec biomedical under pressure: loss of sales and job cuts threaten!

The Stratec Biomedical SE, a diagnostic manufacturer based in Birkenfeld, faces significant challenges. Current reports show that the company had to record considerable loss of sales in the first months of 2025. At the start of the week on April 5, 2025, the share closed at 22.85 euros, which is a new 52-week low after the course had fallen by 3.38% on Friday. In the past month, the share has lost almost 19% in value and since the beginning of the year the losses have even added up to over 23% ( Börse Express ).

The economic difficulties of Stratec are not new and reflect the still existing challenges in the diagnostic sector. The quarterly figures for the first quarter of 2025 disappointed the market expectations. Sales fell by 8.3% to 56.7 million euros, while the adjusted EBIT fell by alarming 27.3% to 4.8 million euros. This corresponds to an EBIT margin of 8.5%. The decline in the core area of ​​the OEM partnerships, which decreased by 12.1%, was particularly serious. The loss of the share of almost 38% within one year shows that fundamental problems remain in the market.

cost savings and restructuring measures

In order to counteract the ongoing market situation, Stratec has initiated a comprehensive restructuring program. The goal is to implement annual cost savings of around 15 million euros by the end of 2026. The measures include a tightening of the product portfolio and the reduction of 150 positions, which corresponds to about 10% of the workforce. These drastic steps are necessary to increase the efficiency and to put the company's financials on a more stable foundation ( Aktiencheck ).

The forecasts for the year 2025 are mixed. While a slight recovery is expected for the second half of the year, a decline in sales in the low single -digit percentage range is also predicted. The average adjusted EBIT margin is to be between 10% and 12% this year, which remains below the company's long-term average. However, analysts are optimistic about the development pipeline, since several product launches are expected in the upcoming quarters.

outlook and market position

Stratec biomedical positions itself in the small cap segment of the medical technology industry. The market capitalization is currently 339.2 million euros. Specialist events such as the Metzler Capital Markets Small Cap Day, in which the company took part in April 3, 2025, offer Stratec the opportunity to get in touch with investors and to present the business strategy. Analysts appreciate the price-profit ratio (KGV) for the 2025 financial year to 15.76, while the current KGV is around 26.12, which indicates a possible improvement in earnings prospects.

The strategic decisions and the adaptation potential will be crucial for whether Stratec Biomedical is able to assert itself in a challenging market environment. While the return to stable growth is still unsure, the measures and previews of product entry that have been initiated could lay the foundation for a positive turn.